bluebird bioBLUE
BLUE
About: bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
Employees: 375
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
731% more call options, than puts
Call options by funds: $40.7M | Put options by funds: $4.89M
3.15% less ownership
Funds ownership: 32.48% [Q3] → 29.33% (-3.15%) [Q4]
28% less capital invested
Capital invested by funds: $33M [Q3] → $23.7M (-$9.32M) [Q4]
42% less funds holding
Funds holding: 137 [Q3] → 80 (-57) [Q4]
77% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 71
95% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 61
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
1%
downside
Avg. target
$6.50
29%
upside
High target
$8
59%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Barclays Gena Wang 21% 1-year accuracy 6 / 29 met price target | 59%upside $8 | Overweight Maintained | 31 Mar 2025 |
Wells Fargo Yanan Zhu 11% 1-year accuracy 1 / 9 met price target | 1%downside $5 | Equal-Weight Maintained | 24 Feb 2025 |
Financial journalist opinion
Based on 17 articles about BLUE published over the past 30 days
Positive
Benzinga
2 days ago
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps
Bluebird Bio, Inc. BLUE received an unsolicited, non-binding written proposal from Ayrmid Ltd. on Friday.
Positive
Reuters
5 days ago
Bluebird bio receives non-binding bid for up to $110.5 million
Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.
Positive
Market Watch
5 days ago
Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update
Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million.
Neutral
Business Wire
5 days ago
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal (the “Ayrmid Proposal”) from Ayrmid Ltd (“Ayrmid”) to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone. As previously announced on February 21, 2025, bluebird entered into a definitive agreement (the “Merger Agreement”.
Negative
Zacks Investment Research
5 days ago
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates
Bluebird Bio (BLUE) came out with a quarterly loss of $23.74 per share versus the Zacks Consensus Estimate of a loss of $6.60. This compares to loss of $15.60 per share a year ago.
Neutral
Accesswire
2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bluebird Bio, Inc. - BLUE
NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
Neutral
PRNewsWire
2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
Neutral
Accesswire
2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
Neutral
Business Wire
2 weeks ago
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if blue.
Neutral
Accesswire
2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
Charts implemented using Lightweight Charts™